...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European review for medical and pharmacological sciences. >Clinical effect of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin
【24h】

Clinical effect of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin

机译：孟鲁司特和阿奇霉素联合治疗小儿肺炎支原体继发哮喘的临床疗效

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To discuss the clinical effects of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin. PATIENTS AND METHODS: 96 children patients diagnosed with secondary asthma attacks of Mycoplasma pneumonia were enrolled in this study. They were randomly divided into two groups: the control group (n=49) and the observation group (n=47). Patients in the control group received combined therapy using azithromycin and bronchodilators or glucocorticoid, and patients in the observation group received a combined therapy of montelukast, azithromycin and bronchodilators or glucocorticoid. The lung function indexes, T lymphocyte subpopulation, cytokines levels, positive rate of lgG and lgM, asthma control rate and recurrence rate were compared between groups before and after treatment. RESULTS: The levels of V-T, t-PTEF/t-E, MTIF/MTEF and TEF25/PTEF in both groups increased after treatment, but we observed a more significant improvement in the observation group. The CD4+ and CD4+/CD8+ levels in both groups also increased after the intervention, while the level of CD8+ decreased. The IL-10, IL-17 and TGF-β levels decreased more intensely in the observation group. DISCUSSION: The positive rate of lgG and lgM in both groups decreased significantly after the intervention. In the observation group, the asthma control rate was higher while the recurrence rate was lower. Although montelukast had little effect on improving the immune function, it was certainly beneficial for controlling the symptoms of asthma and improving the prognosis. CONCLUSIONS: Using combined therapy of montelukast and azithromycin for treating the secondary asthma attacks of children mycoplasma pneumonia can relieve immunological and inflammatory reactions and improve the lung function.
机译：目的：探讨孟鲁司特和阿奇霉素联合治疗小儿肺炎支原体继发哮喘的临床疗效。患者与方法：本研究纳入了96例诊断为继发性哮喘发作的支原体肺炎的儿童患者。他们被随机分为两组：对照组（n = 49）和观察组（n = 47）。对照组患者接受阿奇霉素和支气管扩张药或糖皮质激素的联合治疗，观察组患者接受孟鲁司特，阿奇霉素和支气管扩张药或糖皮质激素的联合治疗。比较治疗前后各组的肺功能指标，T淋巴细胞亚群，细胞因子水平，lgG和lgM阳性率，哮喘控制率和复发率。结果：治疗后两组的V-T，t-PTEF / t-E，MTIF / MTEF和TEF25 / PTEF均升高，但观察组的改善更为显着。干预后，两组的CD4 +和CD4 + / CD8 +水平也均升高，而CD8 +的水平则下降。观察组的IL-10，IL-17和TGF-β水平下降更为强烈。讨论：干预后，两组中lgG和lgM的阳性率均显着下降。观察组哮喘控制率较高，复发率较低。尽管孟鲁司特对改善免疫功能影响不大，但对控制哮喘症状和改善预后肯定是有益的。结论：孟鲁司特联合阿奇霉素联合治疗儿童支原体肺炎继发性哮喘发作可缓解免疫和炎症反应，改善肺功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号